DGAP-News: Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Alliance
Berlin, 13 February 2020. The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) and the Israeli Isotopia Molecular Imaging Ltd. (Isotopia) will in future work more closely together in the early detection of prostate cancer and to this end recently concluded an agreement on the joint development and approval of diagnostic reagents. As part of the agreement, the production of these substances shall soon be fully automated through the use of synthesis systems. "Our synthesis modules simplify the work of physicians and medical physicists, so any expansion of the field of application makes sense," said Dr. Sven-Peter Heyn, Managing Director of Eckert & Ziegler Eurotope GmbH and responsible for the Lab Devices division. "We hope that this step will not only lead to higher sales of synthesis modules in the medium term, but also to a competitive advantage for our gallium generators, which are compatible to the devices. About Eckert & Ziegler. Contact:
13.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 974629 |
End of News | DGAP News Service |
|
974629 13.02.2020
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie erhält starke Unterstützung mit mehreren Buy- und keiner Sell-Einschätzung.
Das Community-Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG zeigt eine potenzielle Verdopplung im Vergleich zum aktuellen Kurs von 41.56 €.